CytoDyn (OTCMKTS:CYDY) Trading Down 3.8% - Here's What Happened

Key Points

• CytoDyn shares fell 3.8%, trading as low as $0.3046 and last at $0.3072 (prior close $0.3195), with about 2.10 million shares traded — roughly a 12% decline from average daily volume.
• The company carries a market capitalization of $394.68 million, a negative P/E of -10.24, a beta of 1.17, and both the 50-day and 200-day moving averages sit at $0.28.
• CytoDyn is a clinical-stage biotech developing the CCR5-blocking monoclonal antibody leronlimab, which is in Phase II/III studies for treatment-resistant HIV and being evaluated in metastatic triple-negative breast cancer and other indications.

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) dropped 3.8% during trading on Tuesday . The company traded as low as $0.3046 and last traded at $0.3072. Approximately 2,104,671 shares were traded during trading, a decline of 12% from the average daily volume of 2,401,561 shares. The stock had previously closed at $0.3195.

CytoDyn Stock Performance

The firm has a market capitalization of $394.68 million, a P/E ratio of -10.24 and a beta of 1.17. The stock has a 50-day moving average of $0.28 and a 200 day moving average of $0.28.

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company's lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.

In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.